[Federal Register Volume 59, Number 141 (Monday, July 25, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-17960]
[[Page Unknown]]
[Federal Register: July 25, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Prospective Grant of Exclusive License: Biomedical Uses of
Compounds of Structure X-[N(O)NO]-, (NONOates) which Spontaneously
Release Nitric Oxide Into a Biological Medium
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
a partially exclusive license, limited by field of use, to practice the
inventions embodied in patents listed below of this notice to
Comedicus, Inc., having a place of business in Long Lake, MN. The
patent rights in these inventions have been assigned to the Government
of the United States of America. The patents and patent applications to
be licensed are:
Title: STABILIZED NITRIC OXIDE PRIMARY AMINE COMPLEXES USEFUL AS
CARDIOVASCULAR AGENTS, U.S. Patent No. 4,954,526
Title: ANTIHYPERTENSIVE COMPOUNDS OF SECONDARY AMINES-NITRIC OXIDE
ADDUCTS AND USE THEREOF, U.S. Patent No. 5,039,705, U.S. Patent No.
5,208,233, and U.S. Patent Application S.N. 8/017,270
Title: ANTIHYPERTENSIVE COMPOSITIONS AND USE THEREOF, U.S. Patent No.
5,212,204
Title: COMPLEXES OF NITRIC OXIDE WITH POLYAMINES, U.S. Patent No.
5,155,137, and U.S. Patent No. 5,250,550
Title: OXYGEN SUBSTITUTED DERIVATIVES OF NUCLEOPHILE-NITRIC OXIDE
ADDUCTS AS NITRIC OXIDE DONOR PRODUCTS, U.S. Patent Application S.N. 7/
764,908 and U.S. Patent Application S.N. 7/950,637
Title: THERAPEUTIC INHIBITION OF PLATELET AGGREGATION BY NUCLEOPHILE-
NITRIC OXIDE COMPLEXES AND DERIVATIVES THEREOF, U.S. Patent No.
5,185,376
Title: MIXED LIGAND METAL COMPLEXES OF NITRIC OXIDE NUCLEOPHILE ADDUCTS
USEFUL AS CARDIOVASCULAR AGENTS, U.S. Patent Application S.N. 7/858,885
Title: POLYMER-BOUND NITRIC OXIDE/NUCLEOPHILE ADDUCT COMPOSITIONS,
PHARMACEUTICAL COMPOSITIONS INCORPORATING SAME AND METHODS OF TREATING
BIOLOGICAL DISORDERS USING SAME, U.S. Patent Application S.N. 7/935,565
and U.S. Patent Application S.N. 8/121,169
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, NIH receives written evidence
and argument that establishes that the grant of the licenses would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Nitric Oxide (NO) has been implicated as an important bioregulatory
mediator in a variety of processes including the normal physiological
control of blood pressure, inhibition of platelet aggregation/adhesion,
bronchodilation, neurotransmission, immunologically induced cytostasis
and penile erection. National Cancer Institute scientists have
discovered that compounds of the structure X-[N(O)NO]-, which will be
designated as ``NONOates'', have the ability to sustain the release of
nitric oxide into a biological medium. Various compounds of this family
have been synthesized and shown to have different kinetics of NO
release. Several of these compounds have been tested in vitro and in
vivo in model systems and have shown potent biological effects.
Requests for a copy of these patent applications, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Ms. Carol Lavrich, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Blvd.,
Rockville, MD 20892. Telephone: (301) 496-7735, ext. 287; Facsimile:
(301) 402-0220. A signed confidentiality agreement will be required to
receive copies of patent applications. Properly filed competing
applications for a license filed in response to this notice will be
treated as objections to the contemplated license. Only written
comments and/or applications for a competing license which are received
by the NIH Office of Technology Transfer within sixty (60) days of this
notice will be considered.
Dated: July 18, 1994.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-17960 Filed 7-22-94; 8:45 am]
BILLING CODE 4140-01-P
